Description
Vassiliki A. Papadimitrakopoulou, MD; Corey J. Langer, MD; and Roy S. Herbst, MD, PhD, discuss the upfront use of pembrolizumab for non–small cell lung cancer with a PD-L1 expression of 50% or more, and review the data from KEYNOTE-024 that lead to FDA approval.
Tags
cancer oncology